Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief

Executive Summary

Biopharma lobbying to include provision to reduce the 70% discount on brands in the budget bill runs out of time, leaving industry evaluating other possible legislative vehicles.

You may also be interested in...



Part D Coverage Gap Discount Relief Misses Ride On Opioids Bill

Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.

Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts

Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.

Point-Of-Sale Rebates In Part D Could Save Seniors $20bn, PhRMA Argues

PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel